BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026

BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2026 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, November 10, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

GlobeNewsWire • Oct 28, 2026

BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives

BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing coverage for the use of BrainsWay Deep TMS™ in the treatment of patients suffering from obsessive compulsive disorder (OCD).

GlobeNewsWire • Oct 26, 2026

BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry Treatments Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry Treatments

GlobeNewsWire • Oct 19, 2026

BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol.

GlobeNewsWire • Oct 13, 2026

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™

Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity

GlobeNewsWire • Sep 8, 2026

Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?

The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Aug 27, 2026

Brainsway (BWAY) Upgraded to Buy: Here's Why

Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Aug 17, 2026

Brainsway Q2 Earnings Call Highlights

Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base.

MarketBeat • Aug 13, 2026

BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript

BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 12, 2026

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

Record  s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025

GlobeNewsWire • Aug 12, 2026